MODULATION OF THE MICRORNA-6089/E2F TRANSCRIPTION FACTOR2 AXIS BY QUERCETIN: IMPLICATIONS FOR OSTEOBLAST VIABILITY, PROLIFERATION, MIGRATION, AND OSTEOGENIC DIFFERENTIATION IN FRACTURE HEALING

被引:1
|
作者
Dong, R. [1 ]
Liu, M. Y. [2 ]
Zhu, G. B. [4 ]
Tan, K. M. [4 ]
Wang, Y. Q. [3 ]
Li, L. [4 ]
机构
[1] Gen Hosp, Anhui Wanbei Coal Elect Grp, Dept Spine Surg, Suzhou, Anhui, Peoples R China
[2] Tianjin Med Univ, Cent Clin Sch 4, Tianjin, Peoples R China
[3] Tianjin Med Univ, Tianjin Cent Hosp 4, Dept Orthoped Surg, 1 Zhongshan Rd, Tianjin 300192, Peoples R China
[4] Gen Hosp, Anhui Wanbei Coal Elect Grp, Gen Clin Res Ctr, 125 Huaihe West Rd, Suzhou 234000, Anhui, Peoples R China
来源
关键词
fracture healing; osteoblasts; quercetin; microRNA-6089; E2F transcription factor 2; osteocalcin; apoptosis; cell proliferation; cell migration; osteoblast; BONE REPAIR; MARKERS; ANTIOXIDANT; NONUNION; BRAIN;
D O I
10.26402/jpp.2024.2.06
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Quercetin is widely distributed in plants as a flavonol compound with multiple biological activities. It has been found that quercetin can regulate bone homeostasis through multiple pathways and targets. This study investigated the role and specific molecular mechanisms of quercetin in regulating osteoblast viability, proliferation, migration and osteogenic differentiation. A mouse model of traumatic fracture was established and then 100 mg/kg quercetin corn oil suspension was gavaged at the same time every day for 28 days. miR-6089 and E2F transcription factor 2 (E2F2) expression levels in mice were measured. Fracture healing in mice was observed. MC3T3-E1 cells were transfected with plasmids targeting miR-6089 and E2F2, and cell viability, proliferation, migration, apoptosis, and osteogenic differentiation were determined. The targeting relationship between miR-6089 and E2F2 was verified. In vivo experiments showed that quercetin significantly increased osteocalcin (OCN) expression (P<0.05) and promoted fracture healing in traumatic fracture (TF) mice. miR-6089 expression was down-regulated (P<0.05) and E2F2 expression was up-regulated (P<0.05) in TF mice. Quercetin promoted miR-6089 expression and inhibited E2F2 expression (both P<0.05). In vitro results showed that quercetin promoted miR-6089 expression and inhibited E2F2 expression in a dose-dependent manner (both P<0.05). Quercetin dose-dependently promoted MC3T3-E1 cell viability, proliferation, migration, and osteogenic differentiation, and inhibited MC3T3-E1 cell apoptosis (all P<0.05). Up-regulating miR-6089 further promoted MC3T3-E1 cell viability, proliferation, migration and osteogenic differentiation, and inhibited MC3T3-E1 cell apoptosis (all P<0.05). miR-6089 targeted and regulated E2F2 expression. Up-regulating E2F2 attenuated the promoting effect of up-regulated miR-6089 on MC3T3-E1 cell viability, proliferation, migration, osteogenic differentiation, and inhibition of apoptosis (all P<0.05). We conclude that quercetin enhances osteoblast viability, proliferation, migration, and osteogenic differentiation by modulating the miR-6089/E2F2 axis, thereby promoting fracture healing.
引用
收藏
页码:173 / 183
页数:11
相关论文
共 19 条
  • [1] MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3
    Ma, Chao
    Han, Jinfeng
    Dong, Dong
    Wang, Nanya
    ONCOLOGY RESEARCH, 2018, 26 (05) : 765 - 773
  • [2] MicroRNA-145-5p inhibits osteosarcoma cell proliferation by targeting E2F transcription factor 3
    Li, Hao
    Pan, Runsang
    Lu, Qiaoying
    Ren, Chong
    Sun, Junkang
    Wu, Huaping
    Wen, Jing
    Chen, Houping
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 45 (05) : 1317 - 1326
  • [3] CircFOXM1 promotes the proliferation, migration, invasion, and glutaminolysis of glioblastoma by regulating the miR-577/E2F transcription factor 5 axis
    Fan, Xuhui
    Liu, Meng
    Fei, Li
    Huang, Zhihui
    Yan, Yufeng
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2022, 22 (02) : 205 - 216
  • [4] RETRACTED: MicroRNA-32 inhibits the proliferation, migration and invasion of human colon cancer cell lines by targeting E2F transcription factor 5 (Retracted Article)
    Yang, F.
    Chen, L.
    Wang, Z-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (10) : 4156 - 4163
  • [5] E2F transcription factor 1 is involved in the phenotypic modulation of esophageal squamous cell carcinoma cells via microRNA-375
    Li, Pengfei
    Lv, Huina
    Wu, Yongkai
    Xu, Ke
    Xu, Min
    Ma, Yegang
    BIOENGINEERED, 2021, 12 (02) : 10047 - 10062
  • [6] MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5
    Xu, Xiupeng
    Cai, Ning
    Zhi, Tongle
    Bao, Zhongyuan
    Wang, Dong
    Liu, Yinlong
    Jiang, Kuan
    Fan, Liang
    Ji, Jing
    Liu, Ning
    AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (08): : 1680 - 1692
  • [7] MicroRNA-32 inhibits the proliferation, migration and invasion of human colon cancer cell lines by targeting E2F transcription factor 5 (vol 23, pg 4156, 2019)
    Yang, F.
    Chen, L.
    Wang, Z-J
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (02) : 568 - 568
  • [8] MicroRNA-544 inhibits esophageal squamous cell carcinoma cell proliferation and enhances sensitivity to cisplatin by repressing E2F transcription factor 5
    Sun, Fengrong
    Zhang, Cuiping
    Ma, Deliang
    Wang, Kai
    ONCOLOGY LETTERS, 2019, 18 (04) : 4203 - 4209
  • [9] E2F transcription factor 5, a new regulator in adipogenesis to mediate the role of Kru<euro>ppel-like factor 7 in chicken preadipocyte differentiation and proliferation
    Jia, Ziqiu
    Jin, Zhao
    Li, Meiqi
    Zhang, Xin
    Peng, Min
    Zhang, Shanshan
    Tan, Ming
    Yang, Qingzhu
    Wang, Weiyu
    Sun, Yingning
    POULTRY SCIENCE, 2024, 103 (06)
  • [10] Circ_0016760 Acts as a Sponge of MicroRNA-4295 to Enhance E2F Transcription Factor 3 Expression and Facilitates Cell Proliferation and Glycolysis in Nonsmall Cell Lung Cancer
    Yan, Xuebo
    Wang, Tong
    Wang, Jiong
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (02) : 147 - 158